奥沙利铂联合替吉奥治疗转移性或不可切除局部晚期三阴乳腺癌的疗效观察

Efficacy of oxaliplatin combined with tegafur for metastatic/unresectable advanced local triple negative breast cancer

目的探讨奥沙利铂联合替吉奥化疗方案治疗转移性/不可切除的局部晚期三阴乳腺癌的临床疗效及对预后的影响。方法选取2018年1月至2019年1月间空军军医大学第一附属医院收治的100例转移性/不可切除的局部晚期三阴乳腺癌患者,采用随机数表法分为观察组和对照组,每组50例。对照组患者采用吉西他滨联合顺铂治疗,观察组患者采用奥沙利铂联合替吉奥治疗,6个周期化疗后,比较两组患者治疗前后血清糖类抗原153(CA153)和癌胚抗原(CEA)变化,统计两组患者生存率及不良反应。结果治疗后,观察组患者治疗总有效率为76.0%,对照组为60.0%,差异无统计学意义(P>0.05)。治疗前,两组患者血清CA153和CEA水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者血清CA153和CEA水平均下降,且观察组均低于对照组,差异均有统计学意义(均P<0.05)。随访6个月,观察组患者生存率为86.0%,对照组为80.0%,两组比较,差异无统计学意义(P>0.05)。观察组患者不良反应发生率为24.0%,对照组为38.0%,两组比较,差异无统计学意义(P>0.05)。结论奥沙利铂联合替吉奥化疗方案治疗转移性/不可切除的局部晚期三阴乳腺癌疗效确切,可有效降低患者血清CA153和CEA水平,提高生存率,改善预后安全性高。

Objective To explore the efficacy of chemotherapy with oxaliplatin combined with tegafur for metastatic/unresectable advanced local triple negative breast cancer.Methods One hundred patients with metastatic/non-resectable advanced local triple negative breast cancer were selected as the study subjects at The First Affiliated Hospital of Air Force Military Medical University from January 2018 to January 2019.They were divided into an observation group and a control group using the random number table method with 50 patients each.The observation group received oxaliplatin combined with tegafur and the control group received gemcitabine combined with cisplatin.Changes in serum carbohydrate antigen 153(CA153)and carcinoembryonic antigen(CEA)were compared between the two groups after 6 cycles of treatment.Survival rates and adverse reactions were calculated.Results After the treatment,the overall efficacy rate was 76.0%in the observation group which was higher than 60.0%of the control group with no significant difference(P>0.05).Before the treatment,there was no significant difference in serum CA153 and CEA levels between the two groups(P>0.05).Compared with before the treatment,serum CA153 and CEA were significantly decreased in the two groups after the treatment and the above indicators were significantly lower in the observation group than in the control group(all P<0.05).After 6-month follow-up,the rate of survival was 86.0%in the observation group and 80.0%in the control group(P>0.05).The incidence of adverse reactions was 24.0%in the observation group and 38.0%in the control group(P>0.05).Conclusion Chemotherapy with oxaliplatin combined with tegafur is effective in the treatment of metastatic/unresectable advanced local triple negative breast cancer,and it can effectively reduce the level of serum CA153 and CEA and improve the survival rate and the prognosis.